Innovacell GmbH
Quick facts
Phase 3 pipeline
- aSMDC · Diabetes
aSMDC is a small molecule that targets the SGLT2 receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: